Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A in Patients With MRD Positive Acute B-cell Leukemia
NCT05350852Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of thiscart19a in B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-Emergent Adverse Events at 2 years. Status: unknown.
02
Drugs
thiscart19a
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05350852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350852.